Bexorg Wins Up to $28.3M ARPA-H Grant for Brain Drug Research
Bexorg secured a federal award of up to $28.3M to extend human brain perfusion technology, potentially transforming CNS drug development.
Bexorg has been awarded a contract worth up to $28.3 million from the Advanced Research Projects Agency for Health (ARPA-H) to advance human brain translational pharmacology, the company announced. The funding is intended to accelerate the development of new treatments for central nervous system disorders by enabling more sophisticated study of living human brain tissue outside the body.
The award is structured in three phases over a 36-month period. Its central objective is to extend the company's BrainEx perfusion platform — a technology that keeps human brain tissue viable outside the body — from its current capability of roughly 24 hours to a duration of up to two weeks. That extended window would allow researchers to conduct longitudinal studies examining how human brain biology changes over time and how it responds to experimental therapeutics.
Read more BillionToOne ctDNA Test Matches Tumor-Informed Rival in Study →
The limitation of existing preclinical models has long been a major obstacle in CNS drug development, where promising compounds frequently fail in human trials after succeeding in animal studies. By sustaining human brain tissue in a functional state for longer periods, Bexorg's platform could give researchers a more accurate biological environment in which to evaluate drug candidates before they ever reach a patient.
The ARPA-H funding underscores the federal agency's mandate to pursue high-risk, high-reward biomedical research that the private sector alone may be unlikely to fund. If the BrainEx extension milestones are met across all three phases, the full $28.3 million would be realized, though phase-gated structures typically require demonstrated progress before subsequent tranches are released.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
